Targeting multiple pathways, which indirectly affect cholesterol balance (and particularly ApoB-containing lipoproteins), may be considered as an additional future therapy of hypercholesterolemia and cardiovascu-lar diseases. The gene discussed is APOB; the disease is familial hypercholesterolemia.